NO20063720L - Antidiabetiske oksazolidiendioner og tiazolidiendioner - Google Patents

Antidiabetiske oksazolidiendioner og tiazolidiendioner

Info

Publication number
NO20063720L
NO20063720L NO20063720A NO20063720A NO20063720L NO 20063720 L NO20063720 L NO 20063720L NO 20063720 A NO20063720 A NO 20063720A NO 20063720 A NO20063720 A NO 20063720A NO 20063720 L NO20063720 L NO 20063720L
Authority
NO
Norway
Prior art keywords
thiazolidinediones
dione
diabetes
type
oxazolidinediones
Prior art date
Application number
NO20063720A
Other languages
English (en)
Norwegian (no)
Inventor
Peter T Meinke
Guo Q Shi
James F Dropinski
Young Zhang
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20063720L publication Critical patent/NO20063720L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C07D263/64—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings linked in positions 2 and 2' by chains containing six-membered aromatic rings or ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20063720A 2004-01-20 2006-08-18 Antidiabetiske oksazolidiendioner og tiazolidiendioner NO20063720L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53763004P 2004-01-20 2004-01-20
PCT/US2005/001344 WO2005070905A1 (en) 2004-01-20 2005-01-18 Antidiabetic oxazolidinediones and thiazolidinediones

Publications (1)

Publication Number Publication Date
NO20063720L true NO20063720L (no) 2006-10-09

Family

ID=34807112

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063720A NO20063720L (no) 2004-01-20 2006-08-18 Antidiabetiske oksazolidiendioner og tiazolidiendioner

Country Status (22)

Country Link
US (1) US20070173434A1 (de)
EP (1) EP1709014B1 (de)
JP (1) JP2007518803A (de)
KR (1) KR20060128921A (de)
CN (1) CN100451008C (de)
AT (1) ATE363475T1 (de)
AU (1) AU2005206540B2 (de)
BR (1) BRPI0506919A (de)
CA (1) CA2553405A1 (de)
CY (1) CY1106757T1 (de)
DE (1) DE602005001265T2 (de)
DK (1) DK1709014T3 (de)
ES (1) ES2287908T3 (de)
IL (1) IL176878A0 (de)
MX (1) MXPA06008190A (de)
NO (1) NO20063720L (de)
NZ (1) NZ548556A (de)
PL (1) PL1709014T3 (de)
PT (1) PT1709014E (de)
RU (1) RU2355682C2 (de)
WO (1) WO2005070905A1 (de)
ZA (1) ZA200605512B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138328A1 (en) * 2005-06-14 2006-12-28 Merck & Co., Inc. Process for the production of antidiabetic oxazolidinediones
CA2612765A1 (en) 2005-07-06 2007-01-18 Merck And Co., Inc. Antidiabetic oxazolidinediones and thiazolidinediones
JP2009502783A (ja) * 2005-07-20 2009-01-29 メルク エンド カムパニー インコーポレーテッド 抗糖尿病性オキサゾリジンジオン及びチアゾリジンジオン
WO2008096769A1 (ja) * 2007-02-08 2008-08-14 Daiichi Sankyo Company, Limited 置換されたセルコスポラミド誘導体を含有する医薬
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
CN111892569A (zh) * 2019-05-05 2020-11-06 石家庄圣泰化工有限公司 4,4’-联-1,3-二氧戊环-2,2’-二酮的合成方法
CN112898265A (zh) * 2019-11-18 2021-06-04 石家庄圣泰化工有限公司 4,4’-联-1,3-二氧戊环-2,2’-二酮的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW268952B (de) * 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
JPH07138258A (ja) * 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US6114526A (en) * 1996-07-01 2000-09-05 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
ID24878A (id) * 1997-12-19 2000-08-31 Merck & Co Inc Turunan ariltiazolidinedion
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase

Also Published As

Publication number Publication date
BRPI0506919A (pt) 2007-06-05
ES2287908T3 (es) 2007-12-16
PL1709014T3 (pl) 2007-10-31
CA2553405A1 (en) 2005-08-04
ATE363475T1 (de) 2007-06-15
ZA200605512B (en) 2007-11-28
CN1910163A (zh) 2007-02-07
NZ548556A (en) 2009-03-31
WO2005070905A1 (en) 2005-08-04
EP1709014A1 (de) 2006-10-11
MXPA06008190A (es) 2006-08-31
RU2006129930A (ru) 2008-02-27
KR20060128921A (ko) 2006-12-14
DE602005001265T2 (de) 2008-01-31
DK1709014T3 (da) 2007-09-10
CN100451008C (zh) 2009-01-14
AU2005206540A1 (en) 2005-08-04
JP2007518803A (ja) 2007-07-12
PT1709014E (pt) 2007-08-13
EP1709014B1 (de) 2007-05-30
DE602005001265D1 (de) 2007-07-12
IL176878A0 (en) 2006-10-31
RU2355682C2 (ru) 2009-05-20
US20070173434A1 (en) 2007-07-26
CY1106757T1 (el) 2012-05-23
AU2005206540B2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2004019869A3 (en) Indoles having anti-diabetic activity
CA2495943A1 (en) Indoles having anti-diabetic activity
WO2004066963A3 (en) N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
MA27317A1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
CY1106757T1 (el) Αντιδιαβητικες οξαζοδιδινοδιονες και θειαζολιδινοδιονες
PE20060415A1 (es) Compuestos heteroaril- y fenilsulfamoilo sustituidos
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
NI200700200A (es) Compuestos aromáticos fusionados con actividad anti-diabética
NO20010628L (no) Substituerte oksazol- og thiazolderivater som hPPAR <gamma> og hPPAR <alfa> aktivatorer
NO20081821L (no) Forbindelser for behandling av metabolske forstyrrelser
BR0213253A (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento de condições mediadas por receptores nucleares e de diabetes tipo i, diabetes tipo ii, dislipidemia, sìndrome x (incluindo a sìndrome metabólica, i.e. tolerância prejudicada à glicose, resistência á insulina, hipertrigliceridemia e/ou ou obesidade), doenças cardiovasculares (incluindo aterosclerose) ou hipercolesteremia
BR0211414A (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas
ATE327983T1 (de) Thia- und oxazole und deren verwendung als ppars- aktivatoren
ATE382043T1 (de) Sulfonamid-derivate als ppar-modulatoren
WO2006014262A3 (en) Indoles having anti-diabetic activity
NO20054396D0 (no) 3-metyl-2-(3-(2-fenyl-oksazol-4-ylmetoksy)-cykloheksankarbonyl-amino)-smorsyrederivater og lignende forbindelser som PPAR-modulatorer til behandling av type 2 diabetes og aterosklerose
DK1789403T3 (da) N-(phenyl-oxazol-4ylmethoxymethyl)-cyclohexyl-ravsyreamid derivater og beslægtede forbindelser som PPAR-ligander (peroxisom-proliferator-aktiverede receptorer) til behandling af hyperlipidæmi og diabetes
HRP20100544T1 (hr) Novi kristal 3-[5-[4-(ciklopentiloksi)-2-hidroksibenzoil]-2-[(3-hidroksi-1,2-benzizoksazol-6-il)metoksi]fenil]propionske kiseline
WO2007018956A3 (en) Antidiabetic oxazolidinediones and thiazolidinediones
WO2006022954A3 (en) Benzoureas having anti-diabetic activity
NO20074738L (no) Aktivator for peroksisom-proliferator som aktiverer reseptor delta
ATE515494T1 (de) Neue verbindungen, deren herstellung und verwendung
DE602005024539D1 (de) Neue verbindungen, ihre herstellung und verwendung
DE602005022585D1 (de) Phenoxyessigsäurederivate als ppar-agonisten
MY139550A (en) Indoles having anti-diabetic activity

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application